Trump purchased up to $5 million in Axon Enterprise stock 14 days before ICE posted a $220M Taser contract tailored to Axon's specifications

On February 10, 2026, President Donald Trump purchased between $1 million and $5 million in Axon Enterprise stock, according to federal financial disclosure forms filed with the Office of Government Ethics on May 8, 2026. Axon is the dominant manufacturer of police body cameras and Taser stun guns in the United States, supplying roughly 90 percent of U.S. law enforcement Tasers and serving as ICE's existing Taser supplier. The disclosure was not public when the purchase occurred; it became public only when the OGE filed the required periodic transaction report.

Fourteen days after the purchase, on February 24, 2026, ICE published a contract solicitation for a five-year, $220 million procurement of approximately 17,800 "conductive energy weapons," along with unlimited cartridges and training. Procurement reviewers and policing experts who examined the solicitation told CNBC that two key specifications — a 45-foot effective range and 10 individually deployable probes — tracked closely with Axon's TASER 10 model and would effectively exclude any rival bidder. The notice did not name Axon, but experts said no competing manufacturer produces a product meeting the stated requirements. If awarded at full value, the contract would more than quadruple ICE's current Taser supply.

Axon's stock rose more than 34% in the seven days following the ICE contract notice. Measured from Trump's February 10 purchase through late June 2026, the shares had climbed approximately 7%, representing an estimated paper gain of up to $350,000 if acquired near the upper end of the disclosed range. Shares had surged more than 22% at their peak before giving back a portion of those gains. Federal procurement records show no contract has been awarded; CNBC reported that the contract's cost and recent turnover in DHS leadership slowed its progress.

The White House said Trump's holdings are maintained in accounts managed by his children and handled by independent third-party financial institutions, and that "there are no conflicts of interest." Ethics experts told CNBC that the concern centers on the appearance of a conflict rather than proof of wrongdoing. There is no public evidence that Trump was involved in shaping the ICE procurement, that acquisition officials were aware of his Axon stake, or that Axon knew the president held its stock. The purchase appeared as part of the broader Q1 2026 OGE disclosure — recorded separately in this archive under federal-monetizing-office-a906adb1 — which showed more than 3,700 individual securities transactions with a cumulative estimated value between $220 million and $750 million.